Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGFβ inhibitor and/or IL-12, where the recombinant cell is gamma (γ)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.
Claims20
A method of treating a cancer or a tumor in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of irradiated recombinant NK-92 cells, wherein the irradiated recombinant NK-92 cells are transfected with one or more nucleic acids that encode
- i) a homing receptor;
- ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen;
- iii) an Fc Receptor;
- and
- iv) a secreted immune modulator selected from a TGFβ inhibitor and/or IL-12,
- wherein the nucleic acid is operably linked to a promoter, and wherein the transfected recombinant NK-92 cell is irradiated with 2.5 to 15 Gy;
- and
- administering the irradiated transfected recombinant NK-92 cell to the subject.
Dependencies are inferred from the claim text.